Orgenesis' CAR-T ORG-101 Demonstrates Efficacy and Safety in Acute Lymphoblastic ...
Orgenesis' ORG-101 CAR-T therapy showed efficacy and safety in 233 CD19+ B-cell ALL patients in China, with 82% CR rate in adults and 93% in children. Severe CRS was observed in 2% of adults and 6% of children. ORG-101 is produced via a decentralized approach and Orgenesis plans a multicenter phase 1/2 trial, starting in Greece.
Highlighted Terms
China’s National Medical Products AdministrationOrgenesisORG-101Legend Biotechmultiple myelomaacute lymphoblastic leukemiarelmacabtagene autoleucel injectionGermany's Paul-Ehrlich-Institutemantle cell lymphomaFDAciltacabtagene autoleucelGeneral University Hospital of PatrasMinistry of Health of IsraelJW TherapeuticsEnterprise Greece Grant
Related News
Orgenesis' CAR-T ORG-101 Demonstrates Efficacy and Safety in Acute Lymphoblastic ...
Orgenesis' ORG-101 CAR-T therapy showed efficacy and safety in 233 CD19+ B-cell ALL patients in China, with 82% CR rate in adults and 93% in children. Severe CRS was observed in 2% of adults and 6% of children. ORG-101 is produced via a decentralized approach and Orgenesis plans a multicenter phase 1/2 trial, starting in Greece.